Australia Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012

Published by: Global Markets Direct

Published: Sep. 30, 2008 - 153 Pages

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 What Is This Report About?

2.2 Definitions

2.2.1 Drug delivery devices

2.2.1.1 Needle-free Injections

2.2.1.2 Inhalation Systems

2.2.1.3 Infusion Systems

3 Healthcare Sector Review

3.1 Healthcare Expenditure

3.2 Healthcare Infrastructure

3.3 Healthcare Policy

4 Drug Delivery Devices in Australia

4.1 Drug Delivery Devices Overall Revenues (2000-2012)

4.2 Drug Delivery Devices Overall Volume (2000-2012)

4.3 Drug Delivery Devices Company Shares (2005-2006)

5 Inhalation Systems in Australia

5.1 Inhalation Systems Overall Revenues (2000-2012)

5.1.1 Metered Dose Inhaler Devices Overall Revenues (2000-2012)

5.1.2 Dry Powder Inhaler Devices Overall Revenues (2000-2012)

5.2 Inhalation Systems Overall Volume (2000-2012)

5.2.1 Metered Dose Inhaler Devices Overall Volume (2000-2012)

5.2.2 Dry Powder Inhaler Devices Overall Volume (2000-2012)

5.3 Inhalation Systems Average Price (2000-2012)

5.3.1 Metered Dose Inhaler Devices Average Price (2000-2012)

5.3.2 Dry Powder Inhaler Devices Average Price (2000-2012)

5.4 Inhalation Systems Distribution Share (2005-2006)

5.5 Inhalation Systems Company Share (2005-2006)

6 Infusion Systems in Australia

6.1 Infusion Systems Overall Revenues (2000-2012)

6.1.1 Infusion Disposable Sets Overall Revenue (2000-2012)

6.1.2 Infusion Pumps Overall Revenue (2000-2012)

6.1.3 Syringe Pumps Overall Revenues (2000-2012)

6.2 Infusion Systems Overall Volume (2000-2012)

6.2.1 Infusion Disposable Sets Overall Volume (2000-2012)

6.2.2 Infusion Pumps Overall Volume (2000-2012)

6.2.3 Syringe Pumps Overall Volume (2000-2012)

6.3 Infusion Systems Average Price (2000-2012)

6.3.1 Infusion Pumps Average Price (2000-2012)

6.3.2 Syringe Pumps Average Price (2000-2012)

6.3.3 Infusion Disposable Sets Average Price (2000-2012)

6.4 Infusion Systems Distribution Share (2005-2006)

6.5 Infusion Systems Company Share (2005-2006)

7 AstraZeneca PLC Company Profile

7.1 Company Overview

7.2 Business Overview

7.2.1 Products

7.2.2 History

7.3 Locations And Subsidiaries

8 3M Company Profile

8.1 Company Overview

8.2 Business Overview

8.2.1 Consumer and Office

8.2.1.1 Overview

8.2.1.2 Capital Expenditure

8.2.1.3 Market View

8.2.1.4 Key Strategies

8.2.2 Display and Graphics

8.2.2.1 Overview

8.2.2.2 Financials

8.2.2.3 Capital Expenditure

8.2.2.4 Market View

8.2.2.5 Key Strategies

8.2.3 Electro and Communications

8.2.3.1 Overview

8.2.3.2 Financials

8.2.3.3 Capital Expenditure

8.2.3.4 Market View

8.2.3.5 Key Strategies

8.2.4 Health Care

8.2.4.1 Overview

8.2.4.2 Financials

8.2.4.3 Capital Expenditure

8.2.4.4 Market View

8.2.4.5 Key Strategies

8.2.5 Industrial and Transportation

8.2.5.1 Overview

8.2.5.2 Financials

8.2.5.3 Capital Expenditure

8.2.5.4 Market View

8.2.5.5 Key Strategies

8.2.6 Safety, Security and Protection Services

8.2.6.1 Overview

8.2.6.2 Financials

8.2.6.3 Capital Expenditure

8.2.6.4 Market View

8.2.6.5 Key Strategies

8.2.7 Products

8.3 Value Chain Analysis

8.3.1 Manufacturing

8.3.1.1 In House Manufacturing

8.3.2 Product Development

8.3.2.1 Regulatory Approvals

8.3.2.2 Clinical Trials

8.3.2.3 Research and Development

8.3.3 Sales and Marketing

8.3.3.1 Partnerships and Alliances

8.3.3.2 Licensing Agreements

8.3.3.3 E-distribution

8.4 SWOT Analysis

8.4.1 3M Company Strengths

8.4.1.1 Strong performance of Industrial and Transportation segment

8.4.1.2 Focused research and development

8.4.1.3 Decentralized operations

3M Company Weaknesses

8.4.1.4 Increased operating costs in the U.S.

8.4.1.5 Personal care segment’s poor performance

3M Company Opportunities

8.4.1.6 Expanding global presence

8.4.1.7 The liquid crystal display

8.4.1.8 Enhancing brand portfolio

3M Company Threats

8.4.1.9 Foreign currency fluctuations

8.4.1.10 Increasing cost of raw materials

8.4.1.11 Trend for private labels

8.5 Revenue Analysis

8.5.1 Revenue by Segment

8.5.2 Revenue by Geography

8.6 Financial and Operational Review

8.6.1 Financial Statements

8.6.2 Financial Ratios

8.7 Locations And Subsidiaries

9 Baxter International Company Profile

9.1 Company Overview

9.2 Business Overview

9.2.1 BioScience

9.2.1.1 Overview

9.2.1.2 Financials

9.2.1.3 Capital Expenditure

9.2.2 Medication Delivery

9.2.2.1 Overview

9.2.2.2 Financials

9.2.2.3 Capital Expenditure

9.2.3 Renal

9.2.3.1 Overview

9.2.3.2 Financials

9.2.3.3 Capital Expenditure

9.2.4 Products

9.2.5 History

9.3 Value Chain Analysis

9.3.1 Manufacturing

9.3.1.1 In House Manufacturing

9.3.2 Product Development

9.3.2.1 Regulatory Approvals

9.3.2.2 Clinical Trials

9.3.2.3 Research and Development

9.3.3 Sales and Marketing

9.3.3.1 Partnerships and Alliances

9.4 SWOT Analysis

9.4.1 Baxter International Inc. Strengths

9.4.1.1 Diversified geographic presence

9.4.1.2 Sturdy research and development activities

9.4.1.3 Strong financial performance

9.4.2 Baxter International Inc. Weaknesses

9.4.2.1 High levels of inventory

9.4.2.2 Decline in revenues of medication delivery

9.4.2.3 Reduced capital expenditure

9.4.3 Baxter International Inc. Opportunities

9.4.3.1 Co-developing alliances

9.4.3.2 Increasing End Stage Renal Disease patients

9.4.3.3 FDA approval

9.4.4 Baxter International Inc. Threats

9.4.4.1 Legal proceedings

9.4.4.2 Patent litigation

9.4.4.3 Stringent regulations

9.5 Revenue Analysis

9.5.1 Revenue by Segment

9.5.2 Revenue by Geography

9.6 Financial and Operational Review

9.6.1 Financial Statements

9.6.2 Financial Ratios

9.7 Locations And Subsidiaries

9.8 Baxter International Inc. Pipeline Products

9.8.1 Next-Generation Home Hemodialysis Machine

9.8.1.1 Product Overview

9.8.1.2 Product Description

9.8.1.3 Product Status

9.8.1.4 Product Milestone

10 GlaxoSmithKline plc Company Profile

10.1 Company Overview

10.2 Business Overview

10.2.1 Products

10.2.2 History

10.3 Locations And Subsidiaries

11 Novartis AG Company Profile

11.1 Company Overview

11.2 Business Overview

11.2.1 Major Products and Services

11.3 Locations And Subsidiaries

12 Regulation System

12.1 Medical Equipment Approval Process

12.1.1 Classification

12.1.2 Registration and Conformity Assessment

12.2 Advertising

12.3 Labeling and Packaging

12.4 Post-market Surveillance

12.5 Registration Fee

13 Pricing and Reimbursement

14 Distribution Structure

15 Recent Developments

15.1 Corporate Communications

15.1.1 Jul 14, 2008: pSivida Appoints New Non-Executive Directors

16 Appendix

16.1 Global Markets Direct Research Methodology

16.2 Coverage

16.3 Secondary Research

16.4 Primary Research

16.5 Models

16.6 Forecasts

16.7 Expert Panels

16.8 Currency Conversion

16.9 Contact Us

16.10 Disclaimer

1.1 List of Tables

Table 1: Healthcare Infrastructure in Australia, 2005

Table 2: Healthcare Personnel in Australia, 2005

Table 3: Hospital Wards by Specialty in Australia, 2003-2007

Table 4: Doctors by Specialty in Australia, 2003-2007

Table 5: Drug Delivery Devices, Australia, Overall Revenues ($ mn), 2000-2012

Table 6: Drug Delivery Devices, Australia, Overall Revenues ($ mn), Historic, 2000-2007

Table 7: Drug Delivery Devices, Australia, Overall Revenues ($ mn), Forecast, 2007-2012

Table 8: Drug Delivery Devices, Australia, Category Revenues ($ mn), 2000-2012

Table 9: Drug Delivery Devices, Australia, Category Revenues ($ mn), Historic, 2000-2007

Table 10: Drug Delivery Devices, Australia, Category Revenues ($ mn), Forecast, 2007-2012

Table 11: Drug Delivery Devices, Australia, Category Volume (Units), 2000-2012

Table 12: Drug Delivery Devices, Australia, Category Volume (Units), Historic, 2000-2007

Table 13: Drug Delivery Devices, Australia, Category Volume (Units), Forecast, 2007-2012

Table 14: Drug Delivery Devices, Australia, Company Share by Revenue ($ mn), 2005-2006

Table 15: Inhalation Systems, Australia, Overall Revenues ($ mn), Historic, 2000-2007

Table 16: Inhalation Systems, Australia, Overall Revenues ($ mn), Forecast, 2007-2012

Table 17: Inhalation Systems, Australia, Revenue by Segment ($ mn), Historic, 2000-2007

Table 18: Inhalation Systems, Australia, Revenue by Segment ($ mn), Forecast, 2007-2012

Table 19: Metered Dose Inhaler Devices, Australia, Overall Revenues ($ mn), Historic, 2000-2007

Table 20: Metered Dose Inhaler Devices, Australia, Overall Revenues ($ mn), Forecast, 2007-2012

Table 21: Dry Powder Inhaler Devices, Australia, Overall Revenues ($ mn), Historic, 2000-2007

Table 22: Dry Powder Inhaler Devices, Australia, Overall Revenues ($ mn), Forecast, 2007-2012

Table 23: Inhalation Systems, Australia, Overall Volume (Units), Historic, 2000-2007

Table 24: Inhalation Systems, Australia, Overall Volume (Units), Forecast, 2007-2012

Table 25: Metered Dose Inhaler Devices, Australia, Overall Volume (Units), Historic, 2000-2007

Table 26: Metered Dose Inhaler Devices, Australia, Overall Volume (Units), Forecast, 2007-2012

Table 27: Dry Powder Inhaler Devices, Australia, Overall Volume (Units), Historic, 2000-2007

Table 28: Dry Powder Inhaler Devices, Australia, Overall Volume (Units), Forecast, 2007-2012

Table 29: Metered Dose Inhaler Devices, Australia, Average Price ($), Historic, 2000-2007

Table 30: Metered Dose Inhaler Devices, Australia, Average Price ($), Forecast, 2007-2012

Table 31: Dry Powder Inhaler Devices, Australia, Average Price ($), Historic, 2000-2007

Table 32: Dry Powder Inhaler Devices, Australia, Average Price ($), Forecast, 2007-2012

Table 33: Inhalation Systems, Australia, Distribution Share (%), 2005-2006

Table 34: Inhalation Systems, Australia, Company Share by Revenue ($ mn), 2005-2006

Table 35: Infusion Systems, Australia, Overall Revenues ($ mn), Historic, 2000-2007

Table 36: Infusion Systems, Australia, Overall Revenues ($ mn), Forecast, 2007-2012

Table 37: Infusion Systems, Australia, Revenue by Segment ($ mn), Historic, 2000-2007

Table 38: Infusion Systems, Australia, Revenue by Segment ($ mn), Forecast, 2007-2012

Table 39: Infusion Disposable Sets, Australia, Overall Revenues ($ mn), Historic, 2000-2007

Table 40: Infusion Disposable Sets, Australia, Overall Revenues ($ mn), Forecast, 2007-2012

Table 41: Infusion Pumps, Australia, Overall Revenues ($ mn), Historic, 2000-2007

Table 42: Infusion Pumps, Australia, Overall Revenues ($ mn), Forecast, 2007-2012

Table 43: Syringe Pumps, Australia, Overall Revenues ($ mn), Historic, 2000-2007

Table 44: Syringe Pumps, Australia, Overall Revenues ($ mn), Forecast, 2007-2012

Table 45: Infusion Systems, Australia, Overall Volume (Units), Historic, 2000-2007

Table 46: Infusion Systems, Australia, Overall Volume (Units), Forecast, 2007-2012

Table 47: Infusion Disposable Sets, Australia, Overall Volume (Units), Historic, 2000-2007

Table 48: Infusion Disposable Sets, Australia, Overall Volume (Units), Forecast, 2007-2012

Table 49: Infusion Pumps, Australia, Overall Volume (Units), Historic, 2000-2007

Table 50: Infusion Pumps, Australia, Overall Volume (Units), Forecast, 2007-2012

Table 51: Syringe Pumps, Australia, Overall Volume (Units), Historic, 2000-2007

Table 52: Syringe Pumps, Australia, Overall Volume (Units), Forecast, 2007-2012

Table 53: Infusion Pumps, Australia, Average Price ($), Historic, 2000-2007

Table 54: Infusion Pumps, Australia, Average Price ($), Forecast, 2007-2012

Table 55: Syringe Pumps, Australia, Average Price ($), Historic, 2000-2007

Table 56: Syringe Pumps, Australia, Average Price ($), Forecast, 2007-2012

Table 57: Infusion Disposable Sets, Australia, Average Price ($), Historic, 2000-2007

Table 58: Infusion Disposable Sets, Australia, Average Price ($), Forecast, 2007-2012

Table 59: Infusion Systems, Australia, Distribution Share by Revenue ($ mn), 2005-2006

Table 60: Infusion Systems, Australia, Company Share by Revenue ($ mn), 2005-2006

Table 61: AstraZeneca PLC, Subsidiaries

Table 62: AstraZeneca PLC, Subsidiaries(Contd..)

Table 63: 3M Company, SWOT Analysis, 2006

Table 64: 3M Company, Revenue by Segment, USD Million, 2003-2007

Table 65: 3M Company, Revenue by Geography, USD Million, 2003-2007

Table 66: 3M Company, Financial Statements, USD Million, 2003-2007

Table 67: 3M Company, Financial Ratios, USD Million, 2003-2007

Table 68: 3M Company, Subsidiaries

Table 69: Baxter International Inc., SWOT Analysis, 2006

Table 70: Baxter International Inc., Revenue by Segment, USD Million, 2003-2007

Table 71: Baxter International Inc., Revenue by Geography, USD Million, 2003-2007

Table 72: Baxter International Inc., Financial Statements, USD Million, 2003-2007

Table 73: Baxter International Inc., Financial Ratios, USD Million, 2003-2007

Table 74: Baxter International Inc., Other Locations

Table 75: Baxter International Inc., Subsidiaries

Table 76: GlaxoSmithKline plc, Subsidiaries

Table 77: Novartis Medical Nutrition, Other Locations

Table 78: Novartis Medical Nutrition, Other Locations(Contd..)

Table 79: Conformity Assessment of Medical Devices based Device Class, in Australia, 2007

Table 80: Fee for Registered Device in Australia, 2007

Table 81: Fee for Device Clinical Trial in Australia, 2007

Table 82: Evaluation Fee for High and Low Level Registration of Medical Device in Australia, 2007

Table 83: Evaluation Fee for Variation Registration of Medical Device in Australia, 2007

Table 84: Fee for Registration of Listed Devices in Australia, 2007

Table 85: Fee for Registration of Listed Devices for Export Only in Australia, 2007

Table 86: Fee for Registration of Included Devices in Australia, 2007

Table 87: Fee for Initial Conformity Assessment of Medical Device in Australia, 2007

Table 88: Fee for Medical Device Changes Conformity Assessment in Australia, 2007

Table 89: Fee for Medical Device Conformity Assessment Surveillance Audit in Australia, 2007

Table 90: Fee for Medical Device Conformity Assessment Review Certificate in Australia, 2007

Table 91: Fee for Initial Conformity Assessment of Medical Device Components in Australia, 2007

Table 92: Fee for Conformity Assessment of Changes in Medical Device Components in Australia, 2007

Table 93: Fee for Abridged Conformity Assessment of Medical Device Components in Australia, 2007

Table 94: Fee for Inclusion of Medical Device in the Register in Australia, 2007

Table 95: Fee for ARTG Inclusion for Medical Device in Australia, 2007

Table 96: Currency Conversion from USD to Local Currency at 2007 Constant Rate 1

1.2 List of Figures

Figure 1: Total Healthcare Expenditure in Australia, 2000 - 2005

Figure 2: Healthcare Financing Framework in Australia, 2007

Figure 3: Healthcare System in Australia, 2007

Figure 4: Drug Delivery Devices, Australia, Overall Revenues ($ mn), 2000-2012

Figure 5: Drug Delivery Devices, Australia, Overall Revenues ($ mn), Historic, 2000-2007

Figure 6: Drug Delivery Devices, Australia, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 7: Drug Delivery Devices, Australia, Category Revenues ($ mn), 2000-2012

Figure 8: Drug Delivery Devices, Australia, Category Revenues ($ mn), Historic, 2000-2007

Figure 9: Drug Delivery Devices, Australia, Category Revenues ($ mn), Forecast, 2007-2012

Figure 10: Drug Delivery Devices, Australia, Category Volume (Units), 2000-2012

Figure 11: Drug Delivery Devices, Australia, Category Volume (Units), Historic, 2000-2007

Figure 12: Drug Delivery Devices, Australia, Category Volume (Units), Forecast, 2007-2012

Figure 13: Drug Delivery Devices, Australia, Company Share (%), 2006

Figure 14: Inhalation Systems, Australia, Overall Revenues ($ mn), Historic, 2000-2007

Figure 15: Inhalation Systems, Australia, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 16: Inhalation Systems, Australia, Revenue by Segment ($ mn), Historic, 2000-2007

Figure 17: Inhalation Systems, Australia, Revenue by Segment ($ mn), Forecast, 2007-2012

Figure 18: Metered Dose Inhaler Devices, Australia, Overall Revenues ($ mn), Historic, 2000-2007

Figure 19: Metered Dose Inhaler Devices, Australia, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 20: Dry Powder Inhaler Devices, Australia, Overall Revenues ($ mn), Historic, 2000-2007

Figure 21: Dry Powder Inhaler Devices, Australia, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 22: Inhalation Systems, Australia, Overall Volume (Units), Historic, 2000-2007

Figure 23: Inhalation Systems, Australia, Overall Volume (Units), Forecast, 2007-2012

Figure 24: Metered Dose Inhaler Devices, Australia, Overall Volume (Units), Historic, 2000-2007

Figure 25: Metered Dose Inhaler Devices, Australia, Overall Volume (Units), Forecast, 2007-2012

Figure 26: Dry Powder Inhaler Devices, Australia, Overall Volume (Units), Historic, 2000-2007

Figure 27: Dry Powder Inhaler Devices, Australia, Overall Volume (Units), Forecast, 2007-2012

Figure 28: Metered Dose Inhaler Devices, Australia, Average Price ($), Historic, 2000-2007

Figure 29: Metered Dose Inhaler Devices, Australia, Average Price ($), Forecast, 2007-2012

Figure 30: Dry Powder Inhaler Devices, Australia, Average Price ($), Historic, 2000-2007

Figure 31: Dry Powder Inhaler Devices, Australia, Average Price ($), Forecast, 2007-2012

Figure 32: Inhalation Systems, Australia, Distribution Share (%), 2006

Figure 33: Inhalation Systems, Australia, Company Share by Revenue ($ mn), 2006

Figure 34: Infusion Systems, Australia, Overall Revenues ($ mn), Historic, 2000-2007

Figure 35: Infusion Systems, Australia, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 36: Infusion Systems, Australia, Revenue by Segment ($ mn), Historic, 2000-2007

Figure 37: Infusion Systems, Australia, Revenue by Segment ($ mn), Forecast, 2007-2012

Figure 38: Infusion Disposable Sets, Australia, Overall Revenues ($ mn), Historic, 2000-2007

Figure 39: Infusion Disposable Sets, Australia, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 40: Infusion Pumps, Australia, Overall Revenues ($ mn), Historic, 2000-2007

Figure 41: Infusion Pumps, Australia, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 42: Syringe Pumps, Australia, Overall Revenues ($ mn), Historic, 2000-2007

Figure 43: Syringe Pumps, Australia, Overall Revenues ($ mn), Forecast, 2007-2012

Figure 44: Infusion Disposable Sets, Australia, Overall Volume (Units), Historic, 2000-2007

Figure 45: Infusion Disposable Sets, Australia, Overall Volume (Units), Forecast, 2007-2012

Figure 46: Infusion Pumps, Australia, Overall Volume (Units), Historic, 2000-2007

Figure 47: Infusion Pumps, Australia, Overall Volume (Units), Forecast, 2007-2012

Figure 48: Syringe Pumps, Australia, Overall Volume (Units), Historic, 2000-2007

Figure 49: Syringe Pumps, Australia, Overall Volume (Units), Forecast, 2007-2012

Figure 50: Infusion Pumps, Australia, Average Price ($), Historic, 2000-2007

Figure 51: Infusion Pumps, Australia, Average Price ($), Forecast, 2007-2012

Figure 52: Syringe Pumps, Australia, Average Price ($), Historic, 2000-2007

Figure 53: Syringe Pumps, Australia, Average Price ($), Forecast, 2007-2012

Figure 54: Infusion Disposable Sets, Australia, Average Price ($), Historic, 2000-2007

Figure 55: Infusion Disposable Sets, Australia, Average Price ($), Forecast, 2007-2012

Figure 56: Infusion Systems, Australia, Distribution Share (%), 2006

Figure 57: Infusion Systems, Australia, Company Share (%), 2006

Figure 58: 3M Company, Value Chain Analysis

Figure 59: Baxter International Inc., Value Chain Analysis

Figure 60: Classification of Medical Devices in Australia, 2007

Figure 61: Classification of Noninvasive Devices in Australia, 2007

Figure 62: Classification of Invasive Devices in Australia, 2007

Figure 63: Classification of Invasive Devices in Australia, 2007

Figure 64: Classification of Active Devices in Australia, 2007

Figure 65: Classification of Special Medical Devices in Australia, 2007

Figure 66: Conformity Assessment Procedure for Medical Devices in Australia, 2007

Figure 67: Global Markets Direct Methodology

Abstract

Australia Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012

Summary

This report is an essential source for in-depth information and data relating to the Australia drug delivery devices market. It also offers detailed and comprehensive coverage of market revenue, volume, distribution and company share information; and latest news, financial deals and pipeline products information of each of the key sub-segments of the drug delivery devices in Australia

Scope

• The report provides drug delivery devices information broken down into detailed categories and segments in Australia.
• Total revenues, products sold, end users, and average pricing.
• Market shares of all the key competitors.
• Key pipeline products that are set to shape the market, broken down by sector.
• Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis, and financial information.
• Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
• Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
• Key mergers and acquisitions, partnerships, private equity investments and IPOs.
• Customer, hospitals and physicians data.

Reasons to buy

• Gain a strong understanding of the drug delivery devices market in Australia.
• Evaluate and compare the attractiveness of the market in the country.
• Identify growth segments and opportunities in each industry sector within the country.
• Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
• Analyze the competitiveness of the market in the country and identify hotspots.
• Develop strategies based on the latest product, brand, expansion and research and development news in the country.
• Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
• Identify and analyze the strengths and weaknesses of the industry incumbents in the country.

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.